Rabbit Polyclonal F13A1(N-Term) Antibody

+ +

•  

   
     All lanes : Anti-F13A1 Antibody (N-Term) at 1:2000 dilution Lane 1: Human lung lysate Lane 2: Human placenta lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG,  (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 83 kDa Blocking/Dilution buffer: 5% NFDM/TBST.    

•  

   
     Immunofluorescent analysis of 4% paraformaldehyde-fixed,  0. 1% Triton X-100 permeabilized A549 cells labeling F13A1 with P34523 at 1/25 dilution,  followed by Dylight® 488-conjugated goat anti-Rabbit IgG secondary antibody at 1/200 dilution (green).  Immunofluorescence image showing cytoplasm staining on A549 cell line. Cytoplasmic actin is detected with Dylight® 554 Phalloidin at 1/500 dilution (red). The nuclear counter stain is DAPI (blue).    

•  

   
     Overlay histogram showing A549 cells stained with P34523(green line).  The cells were fixed with 2% paraformaldehyde (10 min) and then permeabilized with 90% methanol for 10 min.  The cells were then icubated in 2% bovine serum albumin to block non-specific protein-protein interactions followed by the antibody (P34523,  1:25 dilution) for 60 min at 37ºC.  The secondary antibody used was Goat-Anti-Rabbit IgG, DyLight® 488 Conjugated Highly Cross-Adsorbed(1583138) at 1/200 dilution for 40 min at 37ºC.  Isotype control antibody (blue line) was rabbit IgG1 (1μg/1x10^6 cells) used under the same conditions.  Acquisition of >10, 000 events was performed.    

The F13A1 (N-Term) antibody is designed to target the N-terminal region of the coagulation factor XIII A chain (F13A1), a critical enzyme in the blood coagulation cascade. Factor XIII (FXIII) is a transglutaminase composed of two catalytic A subunits (encoded by the F13A1 gene) and two carrier B subunits. Following thrombin activation, FXIII crosslinks fibrin polymers, stabilizing blood clots and promoting wound healing. The F13A1 subunit contains the enzymatic active site, while the B subunit regulates stability and intracellular transport.

The F13A1 (N-Term) antibody specifically recognizes epitopes within the N-terminal domain of the A subunit, enabling detection of both precursor and mature forms of FXIII-A in various applications, including Western blotting, immunohistochemistry, and ELISA. This antibody is widely used in research to study FXIII deficiencies, which are linked to bleeding disorders, impaired wound healing, or thrombotic conditions. It also aids in investigating FXIII's roles beyond hemostasis, such as tissue repair, angiogenesis, and inflammation.

As FXIII-A is expressed in platelets, monocytes, and macrophages, the antibody helps explore its contribution to cardiovascular diseases, fibrosis, and cancer progression. Researchers rely on its specificity to differentiate FXIII-A from other transglutaminases and to analyze post-translational modifications or mutations affecting FXIII function. Proper validation ensures minimal cross-reactivity, making it a valuable tool for mechanistic and diagnostic studies in hematology and vascular biology.